AUG 5, 2026 · PHASE 3 TRIAL
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
ClinicalTrials.gov
This is a Phase 3 trial registration with no posted results; efficacy and safety cannot be assessed from registry data alone.
Reported
Planned enrollment450
PhasePhase 3
Primary outcome measureProgression-Free Survival (PFS), from rando…